FDA Opioid Analgesic Labeling Guidance Will Highlight Drug Abuse Potential
Executive Summary
FDA is developing a guidance on labeling for opioid analgesics, designed to highlight the abuse risk of the drugs.
You may also be interested in...
Long-Term Opioid Efficacy Studies Will Take Years, Gottlieb Says
Trials will be mandated as part of new authority granted by SUPPORT Act and are intended to determine whether opioid efficacy decreases with long-term use.
Ligand Avinza Once-Daily Dosing Will Be Core Promo Message For Elan Opioid
Ligand will focus on Avinza once-daily dosing as the opioid's primary marketing message following the March 20 approval of the extended-release morphine drug licensed from Elan
Ligand Avinza Once-Daily Dosing Will Be Core Promo Message For Elan Opioid
Ligand will focus on Avinza once-daily dosing as the opioid's primary marketing message following the March 20 approval of the extended-release morphine drug licensed from Elan